Alexander J. Martinko

Alexander J. Martinko

Auto-generated profile, based on publicly available information

Alexander J. Martinko

Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
SESusanna K. Elledge
Susanna K. Elledge
XZXin X. Zhou
Xin X. Zhou
JBJames R. Byrnes
James R. Byrnes
AMAlexander J. Martinko
Alexander J. Martinko
ILIrene Lui
Irene Lui
JWJames A. Wells
James A. Wells

23 January 2018 in eLife
Verified
Journal Article
Open access
AMAlexander J Martinko
Alexander J Martinko
CTCharles Truillet
Charles Truillet
OJOlivier Julien
Olivier Julien
JDJuan E Diaz
Juan E Diaz
MHMax A Horlbeck
Max A Horlbeck
JWJames A Wells
James A Wells
While there have been tremendous efforts to target oncogenic RAS signaling from inside the cell, little effort has focused on the cell-surface. Here, we used quantitative surface proteomics to reveal a signature of proteins that are upregulated on cells transformed with KRASG12V, and driven by MAPK pathway signaling. We next generated a toolkit of recombinant antibodies to seven of these RAS-induced proteins. We found that five of these proteins are broadly distributed on cancer cell lines harboring RAS mutations. In parallel, a cell-surface CRISPRi screen identified integrin and Wnt signaling proteins as critical to RAS-transformed cells. We show that antibodies targeting CDCP1, a protein common to our proteomics and CRISPRi datasets, can be leveraged to deliver cytotoxic and immunotherapeutic payloads to RAS-transformed cancer cells and report for RAS signaling status in vivo. Taken together, this work presents a technological platform for attacking RAS from outside the cell.

15 February 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SLShion A. Lim
Shion A. Lim
JZJie Zhou
Jie Zhou
AMAlexander J. Martinko
Alexander J. Martinko
YWYung-Hua Wang
Yung-Hua Wang
EFEkaterina V. Filippova
Ekaterina V. Filippova
JWJames A. Wells
James A. Wells
Extracellular proteolysis is frequently dysregulated in disease and can generate proteoforms with unique neoepitopes not found in healthy tissue. Here, we demonstrate that Abs that selectively recognize a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) could enable more effective and safer treatments for solid tumors. CDCP1 is highly overexpressed in RAS-driven cancers, and its ectodomain is cleaved by extracellular proteases. Biochemical, biophysical, and structural characterization revealed that the 2 cleaved fragments of CDCP1 remain tightly associated with minimal proteolysis-induced conformational change. Using differential phage display, we generated recombinant Abs that are exquisitely selective to cleaved CDCP1 with no detectable binding to the uncleaved form. These Abs potently targeted cleaved CDCP1-expressing cancer cells as an Ab-drug conjugate, an Ab-radionuclide conjugate, and a bispecific T cell engager. In a syngeneic pancreatic tumor model, these cleaved-specific Abs showed tumor-specific localization and antitumor activity with superior safety profiles compared with a pan-CDCP1 approach. Targeting proteolytic neoepitopes could provide an orthogonal “AND” gate for improving the therapeutic index.

24 February 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
AMAlexander J. Martinko
Alexander J. Martinko
ESErin F. Simonds
Erin F. Simonds
SPSuchitra Prasad
Suchitra Prasad
APAlberto Ponce
Alberto Ponce
CBColton J. Bracken
Colton J. Bracken
ZHZachary B. Hill
Zachary B. Hill
Significance: Reported here, we describe a molecular protein technology to enable switchable assembly of functional antibody complexes. This approach, which we call ligand-induced transient engagement (LITE), allows for control of an antibody’s intended function in vivo through the dosing of a small-molecule activator. Chemical regulation of antibody therapeutics represents a treatment paradigm to provide physicians with precise control over the therapeutic activity of a biologic drug after it is administered to a patient. Ultimately, this approach may result in a new class of antibody drugs with improved efficacy and safety profiles and the potential to greatly impact the treatment of human disease.

11 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAlexander J. Martinko
Alexander J. Martinko
HTHai L. Tran
Hai L. Tran
ESErin F. Simonds
Erin F. Simonds
ACAllison L. Cooke
Allison L. Cooke
ZHZhong Huang
Zhong Huang
ZHZachary B. Hill
Zachary B. Hill
We present the Indinavir Ligand Induced Transient Engagement switch (IDV LITE Switch), a fully synthetic Chemically Induced Dimerization (CID) system wherein two humanized antibody fragments are heterodimerized by the antiviral drug indinavir. The IDV LITE Switch represents the first CID system made from fully humanized protein components and dimerized by a clinically approved small molecule drug lacking a mammalian target, making it an ideal bioorthogonal molecular switch for application in small-molecule controlled therapeutics.